Phase 2 Trial Rally: Social media erupted after Avalo Therapeutics reported positive topline results from its Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa. Traders noted strong efficacy like HiSCR75 rates and a cleaner safety profile without neutropenia, fueling a sharp intraday surge on elevated volume. Breakout patterns emerged, with some projecting targets beyond $25 amid biotech sector tailwinds.
Offering Draws Scrutiny: The company's swift $375 million public offering at $17.75 post-data sparked debate over dilution timing. Skeptics called the Phase 2 outcomes borderline and the pricing fair, doubting robust Phase 3 translation. Yet reports of over $3 billion in demand underscored institutional interest.
Mixed Momentum Persists: Optimism clashes with caution as active trading highlights comparisons to rival therapies. Investors track volume and catalysts closely in this volatile name. Broader discussions reflect biotech's high-stakes binary nature.
Note: This discussion summary was generated from an AI condensation of post data.
Avalo Therapeutics Insider Trading Activity
Avalo Therapeutics insiders have traded $AVTX stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $AVTX stock by insiders over the last 6 months:
- MITTIE DOYLE (Chief Medical Officer) has made 0 purchases and 3 sales selling 30,141 shares for an estimated $493,979.
- CHRISTOPHER RYAN SULLIVAN (Chief Financial Officer) has made 0 purchases and 6 sales selling 32,874 shares for an estimated $493,182.
- JONATHAN GOLDMAN has made 0 purchases and 2 sales selling 11,367 shares for an estimated $162,936.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
Avalo Therapeutics Revenue
Avalo Therapeutics had revenues of $59K in Q4 2025. This is a decrease of -69.27% from the same period in the prior year.
You can track AVTX financials on Quiver Quantitative's AVTX stock page.
Avalo Therapeutics Hedge Fund Activity
We have seen 57 institutional investors add shares of Avalo Therapeutics stock to their portfolio, and 27 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG added 664,164 shares (+139.0%) to their portfolio in Q1 2026, for an estimated $9,915,968
- MILLENNIUM MANAGEMENT LLC added 522,548 shares (+380.2%) to their portfolio in Q4 2025, for an estimated $9,489,471
- JENNISON ASSOCIATES LLC added 475,625 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,637,350
- MARSHALL WACE, LLP added 451,541 shares (+806.2%) to their portfolio in Q4 2025, for an estimated $8,199,984
- SOLEUS CAPITAL MANAGEMENT, L.P. added 441,978 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,026,320
- POINT72 ASSET MANAGEMENT, L.P. removed 426,481 shares (-40.5%) from their portfolio in Q4 2025, for an estimated $7,744,894
- BALYASNY ASSET MANAGEMENT L.P. removed 378,124 shares (-46.3%) from their portfolio in Q4 2025, for an estimated $6,866,731
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Avalo Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $AVTX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 05/06/2026
- Guggenheim issued a "Buy" rating on 02/02/2026
- HC Wainwright & Co. issued a "Buy" rating on 01/15/2026
- Mizuho issued a "Outperform" rating on 12/18/2025
To track analyst ratings and price targets for Avalo Therapeutics, check out Quiver Quantitative's $AVTX forecast page.
Avalo Therapeutics Price Targets
Multiple analysts have issued price targets for $AVTX recently. We have seen 6 analysts offer price targets for $AVTX in the last 6 months, with a median target of $49.0.
Here are some recent targets:
- Julian Harrison from BTIG set a target price of $58.0 on 05/06/2026
- Andy Chen from Wolfe Research set a target price of $48.0 on 04/09/2026
- Jason Butler from Citizens set a target price of $52.0 on 04/06/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $40.0 on 03/25/2026
- Yatin Suneja from Guggenheim set a target price of $50.0 on 02/02/2026
- Joseph Catanzaro from Mizuho set a target price of $39.0 on 12/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
